VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Menactra Menomune-A/C/Y/W-135
Vaccine Information Vaccine Information
  • Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
  • Tradename: Menactra
  • Manufacturer: Sanofi Pasteur Inc.
  • Vaccine Ontology ID: VO_0000071
  • CDC CVX code: 114
  • Type: Conjugate vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1725), Canada
  • Host Species for Licensed Use: Human
  • Allergen: Latex
  • Preparation: Cultured on Mueller Hinton agar and grown in Watson Scherp media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration (FDA: Menactra).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
  • Approved Age for Licensed Use: 2-55 years of age.
  • Contraindication: This vaccine should not be administered to anyone with known hypersensitivity to any component of Menactra vaccine including diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components (FDA: Menactra).
  • Description: Contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. Menactra vaccine is not indicated for immunization against diphtheria (FDA: Menactra).
  • Product Name: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W135 Combined
  • Tradename: Menomune-A/C/Y/W-135
  • Manufacturer: Sanofi Pasteur, Inc.
  • Vaccine Ontology ID: VO_0000072
  • CDC CVX code: 32
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1725)
  • Host Species for Licensed Use: Human
  • Antigen: Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
  • Preparation: MEMOMUNE is cultivated with Mueller Hinton agar and Watson Scherp media and is freeze-dried with the group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y and Group W-135 (FDA: Menomune– A/C/Y/W-135).
  • Immunization Route: subcutaneous injection
  • Storage: Store the freeze-dried vaccine and reconstituted vaccine, when not in use, at 2° to 8°C (35° to 46°F).
  • Approved Age for Licensed Use: 2 years of age and older
  • Contraindication: Individuals with known sensitivity to thimerosal or any other component of the vaccine.
  • Description: Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is indicated for active immunization against invasive meningococcal disease caused by these serogroups (FDA: Menomune– A/C/Y/W-135).
Host Response Host Response

Human Response

  • Immune Response: Clinical studies reported antibodies were seen in 90-100% of those who were vaccinated with Menactra (FDA: Menactra).
  • Side Effects: Side effects of vaccination include: injection site reactions, headache, fatigue, irritability and fever.

Human Response

  • Immune Response: Measurable levels of antibodies against the group A and C polysaccharides decrease markedly during the first 3 years following a single dose of vaccine (FDA: Menomune– A/C/Y/W-135).
  • Side Effects: Side effects of vaccination include: pain and redness of injection site, fever and/or headache (FDA: Menomune– A/C/Y/W-135).
  • Efficacy: The serogroup A polysaccharide induces and antibody response in children as young as 3 months of age, the serogroup C component can be poorly immunogenic in recipients who are less than 18 to 24 months of age 5. The serogroups A and C have demonstrated estimated clinical efficacies of 85% to 100% in older children and adults. Serogroups Y and W-135 polysaccharides are safe and immunogenic in adults and in children greater than 2 years of age (FDA: Menomune– A/C/Y/W-135).
References References
FDA: Menactra: FDA: Menactra [https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf]
FDA: Menomune– A/C/Y/W-135: FDA Menomune– A/C/Y/W-135 Neisseria meningitidis vaccine [https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf]